Cargando…
COVID-19 Rebound After Paxlovid Treatment: A Case Series and Review of Literature
Since the declaration of COVID-19 as a pandemic in 2020, several therapies have been developed to reduce symptoms of COVID-19 infection and prevent progression. Paxlovid is an antiviral that was authorized for emergency use in December 2021 for non-hospitalized symptomatic patients with COVID-19 to...
Autores principales: | Alshanqeeti, Shatha, Bhargava, Ashish |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9308388/ https://www.ncbi.nlm.nih.gov/pubmed/35898366 http://dx.doi.org/10.7759/cureus.26239 |
Ejemplares similares
-
Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19:a meta-analysis
por: Wen, Wen, et al.
Publicado: (2022) -
Proxalutamide for the treatment of COVID‐19 rebound following Paxlovid treatment: Report of four cases and review of the literature
por: Yang, Da‐Wei, et al.
Publicado: (2023) -
REBOUND COVID-19 AFTER PAXLOVID IN 2 RELATED FAMILY MEMBERS
por: Periyasamy, P., et al.
Publicado: (2023) -
COVID-19 rebound after Paxlovid and Molnupiravir during January-June 2022
por: Wang, Lindsey, et al.
Publicado: (2022) -
An explanation for SARS-CoV-2 rebound after Paxlovid treatment
por: Perelson, Alan S., et al.
Publicado: (2023)